Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project
Background Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored. Objectives To measure associations between treatment satisfaction and clinical and treatment‐related character...
Gespeichert in:
Veröffentlicht in: | British journal of dermatology (1951) 2022-12, Vol.187 (6), p.927-935 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background
Nearly half of patients with hidradenitis suppurativa (HS) report dissatisfaction with their treatment. However, factors related to treatment satisfaction have not been explored.
Objectives
To measure associations between treatment satisfaction and clinical and treatment‐related characteristics among patients with HS.
Methods
Treatment satisfaction was evaluated utilizing data from a cross‐sectional global survey of patients with HS recruited from 27 institutions, mainly HS referral centres, in 14 different countries from October 2017 to July 2018. The primary outcome was patients’ self‐reported overall satisfaction with their current treatments for HS, rated on a five‐point scale from ‘very dissatisfied’ to ‘very satisfied’.
Results
The final analysis cohort comprised 1418 patients with HS, most of whom were European (55%, 780 of 1418) or North American (38%, 542 of 1418), and female (85%, 1210 of 1418). Overall, 45% (640 of 1418) of participants were either dissatisfied or very dissatisfied with their current medical treatment. In adjusted analysis, patients primarily treated by a dermatologist for HS had 1·99 [95% confidence interval (CI) 1·62–2·44, P |
---|---|
ISSN: | 0007-0963 1365-2133 1365-2133 |
DOI: | 10.1111/bjd.21798 |